The combination of anti‐TREM2 treatment with immunotherapy promotes expansion of immunostimulatory myeloid subsets, enhancing the anti‐tumour activity of immunotherapy such as ICIs or CAR T‐cell therapy.26 The gene discussed is TREM2; the disease is neoplasm.